Giant Roche wades into the preclinical NLRP3 pool, bagging Jecure for their anti-inflammatory team at Genentech
You can now count the biopharma giant Roche among the growing number of players fascinated by the potential of NLRP3 inhibition.
Their big California subsidiary Genentech has snapped up a little San Diego-based biotech called Jecure Therapeutics, which came out of quiet time with a $20 million launch round from Versant and a big appetite for NASH research. The venture group had been drawn in by an experienced biotech team that had built and sold Quanticel to Celgene for close to $485 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
